Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Huang, Shu Pin ^a,b   Bao, Bo Ying ^c,d   Hour, Tzyh Chyuan ^e   Huang, Chao Yuan ^f   Yu, Chia Cheng ^g   Liu, Chia Chu ^a,b   Lee, Yung Chin ^a,b   Huang, Chun Nung ^a,b   Pao, Jiunn Bey ^h   Huang, Chun Hsiung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^h TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 5; CASPASE 3; INSULIN RECEPTOR SUBSTRATE 2;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BMP5 GENE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CASP3 GENE; COHORT ANALYSIS; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; IRS2 GENE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ANDROGENS; BONE MORPHOGENETIC PROTEIN 5; CASPASE 3; COHORT STUDIES; DISEASE PROGRESSION; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84864207278     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041219     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics. CA Cancer J Clin 60: 277-300.
2. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, et al. (2010) Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 21: 1323-1360.
3. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, et al. (2009) Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 41: 1058-1060.
4. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, et al. (2009) Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 41: 1116-1121.
5. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, et al. (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40: 316-321.
6. Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A, et al. (2009) Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 41: 1122-1126.
7. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, et al. (2007) Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 39: 631-637.
8. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, et al. (2008) Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 40: 281-283.
9. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, et al. (2011) Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 43: 570-573.
10. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, et al. (2011) Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 43: 785-791.
11. Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, et al. (2010) Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 42: 751-754.
12. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, et al. (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40: 310-315.
13. Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J, et al. (2009) Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet 41: 1055-1057.
14. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, et al. (2007) Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39: 645-649.
15. Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, et al. (2012) Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy. Int J Cancer 130: 876-884.
16. Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, et al. (2011) Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res 17: 928-936.
17. Huang CN, Huang SP, Pao JB, Chang TY, Lan YH, et al. (2012) Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann Oncol 23: 707-713.
18. Huang CN, Huang SP, Pao JB, Hour TC, Chang TY, et al. (2012) Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. J Intern Med 271: 499-509.
19. Pao JB, Yang YP, Huang CN, Huang SP, Hour TC, et al. (2011) Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer. World J Urol 10.1007/s00345-011-0813-x.
20. Huang SP, Huang LC, Ting WC, Chen LM, Chang TY, et al. (2009) Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 18: 3068-3074.
21. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
22. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, et al. (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24: 3984-3990.
23. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, et al. (2005) Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23: 6556-6560.
24. Storey JD, Tibshirani R, (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445.
25. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, et al. (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818.
26. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW, (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23.
27. Doak SH, Jenkins SA, Hurle RA, Varma M, Hawizy A, et al. (2007) Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Cancer Genet Cytogenet 176: 161-165.
28. Szabolcs M, Keniry M, Simpson L, Reid LJ, Koujak S, et al. (2009) Irs2 inactivation suppresses tumor progression in Pten+/- mice. Am J Pathol 174: 276-286.
29. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, et al. (2007) Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev 21: 2005-2017.
30. Zhang M, Latham DE, Delaney MA, Chakravarti A, (2005) Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24: 2474-2482.
31. Wang P, Dai M, Xuan W, McEachin RC, Jackson AU, et al. (2006) SNP Function Portal: a web database for exploring the function implication of SNP alleles. Bioinformatics 22: e523-529.
32. Bentley H, Hamdy FC, Hart KA, Seid JM, Williams JL, et al. (1992) Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 66: 1159-1163.
33. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, et al. (1994) Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24: 204-211.
34. Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T, et al. (2003) Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54: 268-274.
35. Bergmann U, Funatomi H, Kornmann M, Beger HG, Korc M, (1996) Increased expression of insulin receptor substrate-1 in human pancreatic cancer. Biochem Biophys Res Commun 220: 886-890.
36. Chang Q, Li Y, White MF, Fletcher JA, Xiao S, (2002) Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res 62: 6035-6038.
37. Tanaka S, Wands JR, (1996) A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J Clin Invest 98: 2100-2108.
38. Smith MR, Lee H, Nathan DM, (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91: 1305-1308.
39. Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, et al. (2011) Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 71: 5754-5764.